Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Metsera Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera is focused on developing next-generation medicines to treat obesity and metabolic diseases
Medical Future and Potential Use Researchers believe that retatrutide could play a major role in the future of obesity treatment
The glucagon arm distinguishes it from tirzepatide (GIP/GLP-1 dual) and semaglutide (GLP-1 mono), and is the mechanistic basis for the hepatic fat-oxidation signal, including the reported 86% liver-fat reduction cited in 2026 secondary summaries [1][2] [unverified]
Concentrations vary by pharmacy always verify your specific vial
thus, biopsy is essential
Grant et al
US$ 24.07
US$ 26.55
US$ 25.14
US$ 25.13
US$ 29.76
